Articles tagged with Thalassemia
New research has found that immature red blood cells can import heme from surrounding cells, overcoming long-standing assumptions about heme and red blood cells. This discovery could lead to new therapeutic approaches for inherited genetic blood disorders such as β-thalassemia.
Preliminary results from trials of gene therapy exa-cel suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. The therapy's potential to prevent irreversible complications makes it potentially more beneficial in children than adults.
Treatment with exagamglogene autotemcel (exa-cel) leads to clinically meaningful improvements in overall quality of life for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Patients experience substantial improvements in physical, social, functional, and emotional well-being, with sustained benefits...
Researchers have found a promising new method for gene therapy by bringing dormant genes closer to enhancer switches on the DNA. This 'delete-to-recruit' strategy has potential for treating genetic diseases such as sickle cell disease and beta-thalassemia, offering an alternative to expensive current treatments.
A recent study found that strict adherence to High-Throughput Sequencing (HTS) technology based carrier screening can achieve high efficiency in preventing severe thalassemia birth defects. The study identified 15.07% of women as carriers of thalassemia and confirmed 59 fetuses with severe thalassemia, all of which were in high-risk co...
Genetic testing using high-throughput sequencing (HTS) technology has significantly improved detection rates for thalassemia, offering a valuable model for high-prevalence regions. HTS-based genetic testing offers greater sensitivity and specificity without adding significant costs.
A large-scale thalassemia screening project involving 136,312 individuals revealed a high prevalence of thalassemia in Ganzhou, with 14.545% carriers identified. Next-generation sequencing techniques outperformed conventional methods in identifying novel and rare mutations.
A Phase 3 clinical trial shows that gene therapy can end the need for monthly blood transfusions in children with transfusion-dependent thalassemia. The treatment uses a patient's own stem cells modified with a healthy hemoglobin gene, allowing patients to achieve transfusion-free status within months.
A new assay has been developed to improve prenatal detection of alpha-thalassemia, allowing for clinical diagnosis and large-scale population screening. The one-step nested asymmetric PCR melting curve analysis assay shows high sensitivity and specificity, and can be completed in under 2.5 hours.
A new protocol has increased the rate of successful bone marrow transplants from half-matched donors to nearly 100%, offering a higher chance of cure for patients with severe inherited blood disorders. Patients experienced reduced symptoms and no longer required immunosuppressive medications.
Researchers used a peptide nucleic acid-based gene editing technique to successfully cure a genetic condition in mice. The treatment corrected 6% of mutations and caused dramatic improvements in symptoms, suggesting a promising new approach for treating genetic disorders during early stages of development.
A new gene therapy has successfully treated transfusion-dependent thalassemia, a blood disorder that requires frequent red blood cell transfusions. The treatment produced positive outcomes in an interim analysis of two international clinical trials, with most patients becoming transfusion-free.
Researchers at the University of Zurich discovered that malaria was already widespread on Sardinia in the Roman period, contradicting previous assumptions. Genetic adaptations, such as thalassemias, played a crucial role in protecting against malaria, with some individuals leading healthy lives while being immune to infections.
A new study shows that sofosbuvir and ledipasvir single pill therapy leads to a sustained virological response in 98% of patients with thalassaemia and HCV. The treatment is expected to be limited by drug-to-drug interactions, but offers a significant benefit for these patients.
Researchers developed a novel gene editing strategy to correct thalassemia mutations in mice, alleviating symptoms and normalizing hemoglobin levels. The technique, which uses nanoparticles and synthetic DNA, has the potential to treat people with inherited blood disorders like sickle cell anemia.
The Georgia Health Policy Center has received a $2.7 million grant from the CDC to study transfusion-related complications in patients with hemoglobin disorders, aiming to improve their outcomes. Researchers will explore approaches for reducing complications, developing data-driven solutions, and empowering patients and providers.
A new study found that two beneficial variants of a gene controlling red blood cell development have spread from Africa to nearly all human populations globally. These variants promote fetal haemoglobin production in adulthood, leading to milder symptoms of inherited blood disorders like sickle cell anaemia and thalassaemia.
The NIH Bridging Interventional Development Gaps (BrIDGs) program aims to advance treatments for acute radiation syndrome, brain injury from cardiac arrest, and beta thalassemia. BrIDGs supports expert contractors to perform pre-clinical services, with seven compounds licensed during or after development through the program.
The European Network for Rare and Congenital Anaemia (ENERCA) aims to disseminate latest developments in rare anemias through a network of close contacts. The project has been funded with €1.2 million Euros by the European Commission, and Spain is working on developing a Strategic plan for rare diseases.
Researchers at Mahidol University have created a rapid prenatal test for diagnosing alpha-thalassemia. The new assay boasts high sensitivity and specificity, as well as a decreased risk of contamination, making it suitable for large-scale screening in Southeast Asia.
Thalassemia Foundation of Canada awards Concordia University professor Dr. Peter Pawelek a two-year grant to study a receptor protein found on the surface of a lethal bacterial pathogen that can 'hijack' thalassemia treatment drugs. The research aims to develop new antibiotics to combat opportunistic infections in thalassemia patients.
The NHLBI and CDC are launching a four-year pilot project to study sickle cell disease and thalassemias in six US states. The Registry and Surveillance System in Hemoglobinopathies (RuSH) project aims to gather comprehensive demographic data on people with these life-threatening diseases.
A new study shows that transferrin, a blood protein, can alleviate anemia and prevent fatal iron overload in humans. The research, conducted at Albert Einstein College of Medicine, suggests that treatment with transferrin could benefit people with thalassemia and other types of anemia.
Researchers have identified a gene that directly affects the production of fetal hemoglobin, which could lead to the development of new therapies for sickle cell disease and thalassemia. By suppressing a specific gene called BCL11A, HbF production improves dramatically, providing a potential new target for treatments.
Weill Cornell researchers discovered a gene responsible for mutated red blood cells in Cooley's anemia, allowing mice to produce normal red blood cells without splenectomy. The study found that blocking the JAK2 gene reduces spleen size and improves hemoglobin production.
A new study reveals that children with a mild form of alpha thalassemia have more red blood cells, which provides an advantage against life-threatening malarial anemia. This adaptation allows them to tolerate massive blood cell loss during severe malaria attacks.
Researchers identified GDF15 protein as a key player in iron overload in thalassemia, leading to increased dietary iron absorption and organ damage. The study's findings have implications for therapies and treatment strategies for thalassemia patients.
Research by Dr. Anthony Argentaro has advanced understanding of ATRX mutations that cause blood disorders and genital abnormalities in boys, finding excess or deficiency leads to developmental issues.
Ferriprox has been shown to provide significantly better cardio-protection compared to deferoxamine, reducing heart iron concentrations and improving cardiac function in thalassemia patients. The study findings suggest that Ferriprox's small structure provides a greater potential to chelate intracellular iron in the heart.
Regular cardiac monitoring and prompt treatment can prevent and reverse severe heart dysfunction in thalassemia major patients. The study found that intensive deferoxamine mesylate treatment significantly improved survival rates among those who complied with therapy.
Researchers found that administering hydroxyurea to patients with severe forms of beta-thalassemia boosted hemoglobin levels and enabled five patients to stop undergoing transfusions. The treatment also improved quality of life for the children, who reported feeling better and more active.
Researchers found that prenatal HLA typing can identify compatible donors, enabling early treatment for affected fetuses. The technique has the potential to save thousands of lives by treating a common blood disorder with bone marrow transplantation.
The Children's Hospital of Philadelphia has been awarded a federal grant to monitor the nation's blood supply for new infectious agents, particularly relevant for thalassemia patients who require frequent blood transfusions. The program will also expand its efforts to identify new patients with thalassemia and provide comprehensive ser...
Researchers have discovered a protein, alpha hemoglobin stabilizing protein (AHSP), that binds to free alpha globin and prevents it from forming a precipitate that damages red blood cells. This discovery may lead to a new treatment for thalassemia by reducing the need for frequent blood transfusions.
Researchers used antisense oligonucleotides to block defective genes responsible for producing hemoglobin, restoring correct production of beta-globin and enabling cells to produce more hemoglobin. The correction could last for months and may be a simpler therapy than gene therapy.
A new oral medication called deferiprone has been shown to have a rare side effect on white blood cells, but is considered a potential treatment option for patients with iron overload. The study found that the drug may benefit patients with thalassemia and other hemoglobin disorders who do not respond to conventional treatments.